Motor finance customers could receive payout as FCA will consult on scheme
Many motor finance firms were not complying with rules or the law by not providing customers with relevant information about commission paid by lenders to the car dealers who sold the loans, the FCA said.
It comes after Friday's ruling by the Supreme Court on cases in which the FCA had intervened.
While some motor finance customers will not get compensation because in many cases commission payments were legal, the court ruled that in certain circumstances the failure to properly disclose commission arrangements could be unfair and therefore unlawful, the FCA added.
The UK's highest court ruled that car dealers did not have a relationship with their customers that would require them to act 'altruistically' in the customers' interest.
Nikhil Rathi, chief executive of the FCA, said: 'It is clear that some firms have broken the law and our rules. It's fair for their customers to be compensated.
'We also want to ensure that the market, relied on by millions each year, can continue to work well and consumers can get a fair deal.
'Our aim is a compensation scheme that's fair and easy to participate in, so there's no need to use a claims management company or law firm. If you do, it will cost you a significant chunk of any money you get.
'It will take time to establish a scheme but we hope to start getting people any money they are owed next year.'
The FCA currently estimates that most individuals will probably receive less than £950 in compensation.
The final total cost of any compensation scheme is currently estimated to be between £9 billion and £18 billion, the FCA added.
The consultation will launch by early October. If the compensation scheme goes ahead, the first payments should be made in 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
29 minutes ago
- Bloomberg
British Tech Unicorn Quantexa Eyes IPO as Soon as 2026
British data and analytics software startup Quantexa is considering an initial public offering as soon as the second half of next year, people with knowledge of the matter said. The London-based company could seek a valuation of more than $3 billion in the potential listing, said the people, who asked not to be identified as the information is private. The US is among listing venues being considered, though no final decision has been made, the people said.
Yahoo
43 minutes ago
- Yahoo
Car finance scandal payouts ‘will harm Britain's prospects'
A car finance compensation scheme that risks leaving the City with a bill of up to £18bn will hammer Britain's prospects as a place to invest, lenders have warned. John Phillipou, chairman of the Finance & Leasing Association, said offering compensation to customers on deals dating back nearly two decades would harm the UK's 'investability'. He said it would be 'impossible' for banks to obtain data dating back to 2007 because businesses are already encouraged to delete loan information under data protection rules. Mr Phillipou said: 'The outline of the redress scheme is impractical and going back to 2007 is going to be impossible to get that data. If you're running your businesses properly, we encourage them to follow the GDPR rules. Then you haven't got the reason to retain that data. 'I don't think it's good for UK investability that the reason for keeping the data is that you might get sued in 15 years time. 'I understand the doing right by the consumer but one of the things is showing loss to consumers. That's going to be quite hard to prove without paperwork and evidence'. The Financial Conduct Authority (FCA) on Sunday said motorists who had taken out loans to pay for their vehicles which included secret commission agreements between banks and dealers could be in line for payments of up to £950 under a redress scheme. Lenders could be forced to pay between £9bn and £18bn to customers who were mis-sold car finance. The FCA is now consulting on the proposals. Many banks that provided loans to car buyers failed to properly disclose the details of the schemes. On Friday, the Supreme Court rejected claims this commission amounted to a bribe, but ruled some rates had been excessive and unfair. Bank shares surged on Monday as markets opened for the first time since the Supreme Court's judgment. Shares in Lloyds Bank, the UK's biggest car finance lender, were up 6pc. Shares in Close Brothers, a specialist lender, jumped as much as 25pc to 494p. Mr Phillipou, who was speaking on a webinar hosted by Asset Finance Connect, said the 3pc rate of interest proposed by the FCA would also be a 'massive topic' for the group. 01:22 PM BST That's all for today Thanks for joining us this morning. To quickly re-cap: The Supreme Court's decision on the car finance scandal has sent shares in some of Britain's biggest lenders, including Lloyds Bank, soaring. However, questions still remain on how the Financial Conduct Authority will handle a redress scheme worth as much as £18bn, which industry leaders risked being 'completely impractical'. Stephen Haddrill, director general of the Finance & Leasing Association said the industry had a 'major concern about the redress scheme going back to 2007'. He told the BBC's Today programme: 'I just think that is completely impractical. It is not just firms that don't have the details about contracts back then, customers don't either.' 01:06 PM BST Can I get compensation for my car finance? The Financial Conduct Authority's consultation means people who took out car finance on unfair terms could be eligible for up to £950 in compensation. However, for now, the best advice is to sit tight and wait for more details, rather than signing up to a claims management firm. Telegraph Money explains what you should and shouldn't do next... 12:28 PM BST Dealmaking could follow Supreme Court ruling, lawyer suggests The Supreme Court's decision to block the majority of claims against the car finance industry could unlock a wave of dealmaking between dealerships and finance providers, a City lawyer has said. Hyder Jumabhoy, a partner at White & Case LLP who leads its financial institutions group, said:' Investors are comforted that a path through the uncertainty has emerged. While it is too early to predict the full impact with certainty until the FCA's consultation process is complete, we expect this move to accelerate M&A activity due to some lenders having decreased risk appetite but also because of unused provision amounts becoming available for acquisitions. 'It could also prompt some car manufacturers to enter the UK motor finance market to steady the supply of finance to buyers of new vehicles.' 11:46 AM BST Motor finance compensation will hurt UK 'investability' Plans to force lenders to pay compensation to millions of car finance customers dating back almost two decades risk hurting Britain's 'investability', an industry body has claimed. John Phillipou, the chair of the Finance and Leasing Association, said: 'The outline of the redress scheme is impractical and going back to 2007 is going to be impossible to get that data. We're all encouraging them, if you're running your businesses properly, to follow the GDPR rules and then if you haven't got the reason to retain that data.'I don't think it's good for UK investability that the reason for keeping the data is that you might get sued in 15 years time.'I understand the doing right by the consumer but one of the things is showing loss to consumers. That's going to be quite hard to prove without paperwork and evidence'. 11:39 AM BST Lloyds shares up 7.5pc Shares in Lloyds have continued to climb this morning and are now up 7.5pc as the market welcomes the Supreme Court's decision on Friday. 11:03 AM BST City watchdog to take 'moderate approach', analysts predict The City's financial regulator is expected to take a 'moderate approach' when it comes to compensation claims from motorists, analysts at RBC have said. 'We see Friday's Supreme Court judgement as a clearing event for the bank and expect the FCA to take a moderate approach when laying out its final redress scheme towards the end of this year,' analysts at the bank said in a note. They added: 'It's hard to see Lloyd's underperforming into the medium term given rate expectations and a softening regulatory backdrop.' 10:30 AM BST 'Extraordinary intervention' by FCA could still cost banks billions, analysts say The UK finance watchdog's mass redress scheme has been labelled an 'extraordinary intervention' because banks may still be forced to put more cash aside. Analysts at Keefe, Bruyette and Woods said the Financial Conduct Authority's £9bn to £18bn estimate would force Close Brothers to increase provisions from £165m to £285m and Lloyds from £1.2bn to £2bn. KBW said it was surprising banks were being asked to put more aside by the FCA despite lenders already having earmarked £2bn to cover the costs of the issue. 'Instinctively one might have thought that that would leave management's existing litigation provision sufficient, but the FCA's extraordinary intervention on Sunday afternoon suggests that further provisions may still be required - albeit still well below our pre-Supreme Court assessment,' they said about Close. They were surprised about Lloyds' having to pay more, because the FCA had already backed the '£1.2bn provision'. 'Quite why regulators agreed Lloyds' £1.2bn earlier in the year if they thought the liability was so much higher is not explained,' they said, adding that Lloyds had a 'long track record of understating litigation risk)'. 09:59 AM BST Car finance compensation will hit profits, South African bank warns FirstRand, the South African owner of car finance giant Motonovo, has warned investors that the UK car payout scheme could weigh on profits. On Monday, the lender said it may need to set aside more money than expected after the Financial Conduct Authority unveiled plans for a mass redress scheme, Michael Bow reports. In particular, the bank said predicted earnings growth of 'low double digits to mid teens' - roughly 10pc to 15pc - would not 'trend closer to the bottom end' of the guidance, meaning closer to 10-11pc. Much will hinge on the FCA's proposed interest penalty of around 3pc for the redress scheme, it indicated. Despite the threat, shares in the Johannesburg lender spiked 6pc this morning. Motonovo is a major UK car finance lender, and FirstRand was one of the company's being sued as part of Friday's Supreme Court case. 09:43 AM BST 'Victory for common sense' in car finance case, says lender The founder of a specialist finance lender which saw shares battered by the motor finance controversy has praised the outcome as a 'victory for common sense', Michael Bow reports. Anthony Coombs, a former Tory MP and now chair of lender S&U, said the watchdog-led redress scheme was 'entirely consistent' with the Government's growth mission. S&U shares tanked 33pc in the wake of the Court of Appeal judgment last October amid fears its lending practices would be caught up in a redress scheme. Shares have bounced back since and rose nearly 14pc on Monday after the Supreme Court overturned the ruling, and S&U said any impact would be 'minimal'. Mr Coombs said: 'It will significantly boost confidence throughout the motor finance industry and benefit lenders and consumers alike in attracting investment and increasing competition. As such, it is entirely consistent with the Treasury's recent emphasis on regulation which encourages growth.' 09:24 AM BST Car finance compensation 'credit negative' for banks, says Moody's Car finance payouts will be 'credit negative' for Britain's banks after the expected compensation sums came in higher than expected, a leading ratings agency warned. Moody's said the UK finance watchdog's redress scheme, announced on Sunday, would lead to 'substantial compensation payouts for lenders' and hurt balance sheets, Michael Bow writes. Simon Ainsworth, from Moody's, said: 'The FCA's decision to proceed with a consultation for a redress scheme on motor finance commissions is credit negative for UK banks and other consumer credit providers. He added lenders had already put aside £2bn - but the estimated £9bn to £18bn cost of the scheme meant banks would have to take a bigger hit. Before the Supreme Court ruling, Moody's had originally predicted the compensation hit could have hit £30bn. Judges on Friday dramatically narrowed the scope of the scheme. 09:03 AM BST Shares in Close Brothers climb 21pc on car finance ruling Shares in specialist lender Close Brothers are flying on Monday morning as investors unpack the Supreme Court's decision late last week to reject the majority of car finance compensation claims. The lender climbed as much as 25pc in early trades and is now trading up around 21pc at 481p. Close Brothers was one of the lenders most exposed to he scandal. Roughly 20pc of its loan book was dedicated to car finance and the mid-market lender had set aside £165m to cover anticipated losses from claims. However, the Supreme Court's decision to dismiss blanket calls for compensation for mis-sold car finance have reassured investors in the lender. Close Brothers lost close to 50pc of its value in the days following a court ruling in October that left it exposed to a vast compensation payout. Its shares have now recovered that lost value, giving it a market capitalisation of £720m. In a statement, Close Brothers said it was still considering the financial impact of Friday's decision and the FCA's consultation on redress. It said: 'Until the FCA confirms whether it will consult on a redress scheme and, if so, confirms the design and scope of that scheme, there remains uncertainty as to the range of outcomes, and the financial impact to the group, including any impact on its provisioning assessment.' 08:34 AM BST Lloyds expects to pay more than £1bn in compensation Lloyds Bank has confirmed it still expects to pay more than £1bn in compensation over the motor finance scandal, despite Friday's Supreme Court ruling. In a statement on Monday, the lender, which is the UK's biggest car finance firm through its Black Horse division, said the scale of payouts was expected to be broadly similar to its earlier estimates given to investors. The bank said: 'After initial assessment of the Supreme Court judgment, and pending resolution of the outstanding uncertainties, in particular the FCA redress scheme, the group currently believes that if there is any change to the provision it is unlikely to be material in the context of the group. 'The provision will continue to be reviewed for any further information that becomes available, with an update provided as and when necessary.' The bank has already set out a provision of around £1.15bn for compensation claimants. Lloyds shares were up 6pc on Monday morning. 08:24 AM BST Bank shares surge after Supreme Court ruling Shares in some of Britain's biggest lenders are surging this morning after the Supreme Court rejected the majority of motor finance claims in a ruling on Friday. Lloyds Bank shares were up 6pc in early trading in London, while shares in specialist lender Close Brothers climbed 25pc. Shares in Secure Trust Bank were up 19pc while shares in Barclays were up 1.8pc. Lloyds is Britain's biggest car finance lender through its Black Horse division. The share price jump comes after a court ruling that was handed down after markets closed on Friday, largely throwing out claims for compensation brought over mis-sold car loans. The Supreme Court's judgment was delayed to avoid turbulence in the City given fears the claims could give rise to compensation payouts of as much as £44bn. Over the weekend, the FCA said the scale of redress payouts under a new scheme being pulled together by the watchdog would be in the region of £9bn to £18bn. 08:14 AM BST Do not hire a law firm for motor finance, says FCA chief Consumes should avoid hiring a law firm or claims management company to handle their compensation claim for car finance, the chief executive of the Financial Conduct Authority has said. Nikhil Rathi, the head of the City watchdog, said: 'You don't need to use a claims management company or law firm.' He said the FCA had already taken action against '225 adverts because there have been exaggerated claims out there' of compensation that could be on offer. However, he added consumers still deserved redress, despite the Supreme Court's decision to throw out the majority of claims last week over motor finance. 'We have found in our review that many firms broke the law,' Mr Rathi told the BBC. 'In those cases where consumers have lost out it is important that there is appropriate compensation.' He said there were grounds to go back to 2007 to avoid 'thousands of cases' going through the courts in order to 'bring this to a close now given that his has been argued about for several years'. 07:48 AM BST Car finance compensation will hit borrowing costs, lenders warn Good morning, the fall out from the car finance scandal has continued this morning as lenders digest plans for a compensation scheme that could leave them on the hook for up to £18bn. Uncertainty over the compensation payouts could increase borrowing costs, lenders have warned, after Financial Conduct Authority (FCA) on Sunday announced a consultation on how customers could seek redress for mis-sold laons. Stephen Haddrill, director general of the Finance & Leasing Association, warned that questions over how a redress scheme will award payments dating back as far as 2007 would increase lending costs. He told the BBC: 'The more uncertainty there is for people who finance the car finance industry, the more expensive that finance becomes for the firms and ultimately the more expensive borrowing becomes for the customer.' Over the weekend, Nikhil Rathi, chief executive of the FCA, said: 'It is clear that some firms have broken the law and our rules. It's fair for their customers to be compensated. We also want to ensure that the market, relied on by millions each year, can continue to work well and consumers can get a fair deal.' The Supreme Court last week through out the majority of claims related to car finance schemes, ruling that commission awarded to car dealers by lenders in secret was not a bribe. However, the FCA said it still wanted to ensure customers were 'consistently, efficiently and fairly' awarded compensation if they were wrongly sold certain types of loans for buying cars. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
